In a recent article published in the Agefi, the year 2023 saw a rise in mergers and acquisitions in the biotech sector, despite a slowdown in IPOs. While 2024 promises to be an optimistic year, investors are urged to be cautious about the haste of start-ups to go public.
2024: a promising year for biotech Read More »
Meet IHMA at the 2024 ECCMID conference in Barcelona from April 27 to 30, 2024. Rendez-vous at the booth Stand E67 ! Based on the Monthey-site of BioArk, the company IHMA is specialized in infectious diseases & offer the most comprehensive offering of products and services for developing and marketing antimicrobial agents. From April 27
IHMA Exhibiting and Presenting at ECCMID 2024 Read More »
Orio Therapeutics, a biotechnology company at the forefront of protein engineering for regenerative medicine, today announced the successful closure of a CHF 500,000 pre-seed funding round. This investment, secured from angel investors, will propel the company’s ambitious goal of revolutionizing treatment approaches for patients suffering from debilitating conditions.
ten23 health, based in Basel and at the BioArk Visp, and SHL Medical, a world-leading provider of drug delivery devices, announced their strategic partnership to provide a streamlined offering for pharmaceutical and biotech companies that require sterile drug/device combination products.
Presse release – Visp, Switzerland, March 22, 2024 – In March 2023, MINTworld, a platform dedicated to discovery and innovation, was inaugurated in Visp. In a public-private partnership, the canton of Valais, BioArk Viège AG and Lonza are committed to promoting the enjoyment of technology and science within the community, and to creating a platform
MINTworld celebrates a successful first year Read More »
Swiss CDMO ten23 health has announced in its press release that its large-scale pre-filled syringe, cartridge and vial aseptic filling line 2 (VIVA2) in Visp (Switzerland) will be GMP operational by end 2024! Located near by our Visp technological site of BioArk, the ten23 Health’s expansion, previously first announced in June, 2022 is now completing
ten23 health’s expansion in Visp will be operational by en 2024 ! Read More »
The past week has been a landmark occasion for the Monthey startup REM Analytics, as they were selected to present their cutting-edge Advanced Testing for Genetic Composition technology platform on stage at the major Probiota 2024 congress. Discover this innovative nugget and its technology ! First of all, a few words about REM Analytics.
Get to know the new Probiota Pionneer: REM Analytics ! Read More »
The purpose of this exchange between the municipality of Monthey and Satom is twofold. A large part of the site of the former Djevahirdjian factory, which closed its doors in 2021 after one hundred and seven years of activity in the manufacture of synthetic gemstones, is now in municipal hands. The Satom company, which had
Monthey City acquires the Djeva site for BioArk future technology park Read More »
Lonza reports revenues of 6.7 billion Swiss francs, CER growth of 10.9%1 , and CORE EBITDA of 2 billion Swiss francs, establishing a margin of 29.8%. At the same time, the appointment of Jean-Marc Huët to succeed Albert M. Baehny as President of the company is made official. Albert M. Baehny, Chairman of the Board
Solid financial 2023 results for Lonza, with investments in Visp ! Read More »
Stämm, an innovative leader in bioprocessing technology, has announced the opening of its new R&D facility at the technological site of BioArk in Monthey. With the establishment of its new R&D facility in Valais(Switzerland), Stämm is set to bring its pioneering technology to the heart of Europe’s thriving biotech sector. The new facility at BioArk
BioArk Monthey welcomes the new R&D center of Stämm ! Read More »
Sion Site
Rue de l’Industrie 23
CH-1950 Sion
Tél. +41 (0) 58 332 21 20
info@bioark.ch
Monthey Site
Rte de l’Ile-au-bois 1A
CH-1870 Monthey
Tél. +41 (0) 58 332 21 20
info@bioark.ch
Massimo Nobile
| BioArk | Intranet BioArk Monthey
